Repros Therapeutics Inc., of The Woodlands, Texas, said the FDA recommended a Phase IIb study of Proellex-V, a product in development by for uterine fibroids, before proceeding to Phase III

Insys Therapeutics Inc. (NASDAQ:INSY) debuted at $8 per share, and has surged as high as $11.39 since then, with its last close at $10.18...Stemline Therapeutics Inc., of New York, closed a public offering of 4,137,931 shares of common stock at $14.50 per share

Halozyme Therapeutics Inc., of San Diego, said the European Commission granted partner Baxter International Inc., of Deerfield, Ill., marketing authorization in all European Union (EU) member states for the use of HyQvia (solution for subcutaneous use) as replacement therapy for adults with primary and secondary immunodeficiencies...Proteostasis Therapeutics Inc., of Cambridge, Mass., presented data on its preclinical targets for Parkinson's disease and cystic fibrosis (CF) at a conference hosted

Ico Therapeutics Inc., of Vancouver, British Columbia, said it closed its overnight marketed offering, pricing about 9.7 million units at C35 cents (US34 cents) apiece for aggregate gross proceeds of C$3.4 million

Baliopharm GmbH, a subsidiary of Baliopharm AG, of Basel, Switzerland, joined the NEU2 Consortium with a project addressing the recombinant manufacturing of an Fc-free bispecific CD20-CD95 antibody construct (Novotarg) with selectivity for activated B cells and efficacy studies in disease models relevant to multiple sclerosis therapy. The two-year project was funded by the German Federal Ministry of Education and Research. Bayer AG, of Leverkusen, Germany, signed an agreement to acquire the